RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

 

Article type: Editorial

Keywords: Cancer World magazine, .

This article has 1 comments

Facebook Twitter Share - Send - Print - Pdf

 

Welcome to our World

Welcome to our World

Welcome to Cancer World – the magazine for the European oncology community. Cancer World was formerly published as Cancer Futures – it has a new name and a new look, but its aim is the same: to help reduce the unacceptable number of deaths from cancer that are caused by late diagnosis and inadequate cancer care

» Kathy Redmond

To read complete article please click on the pdf icon
 
COMMENTS (1)
 
Adriane (our world) says: 11 October 2011 03:11:35
After reading a few of your editorials I was disappointed because there wasn't much to the articles. As for the "world" part there is not much n how each country is doing with cancer ups and downs.
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.